CNBX Pharmaceuticals Inc.
CNBX
$0.0005
$0.000125.00%
OTC PK
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -91.87% | -68.31% | -32.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -91.87% | -68.31% | -32.39% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -100.00% | -93.11% | -69.82% | -34.22% |
| SG&A Expenses | -52.09% | -49.71% | -47.57% | -43.03% | -48.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -78.92% | -75.56% | -61.09% | -46.84% | -41.94% |
| Operating Income | 71.91% | 57.03% | 40.78% | 37.40% | 44.56% |
| Income Before Tax | 81.42% | 76.03% | 84.39% | 81.26% | 66.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 81.42% | 76.03% | 84.39% | 81.26% | 66.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.42% | 76.03% | 84.39% | 81.26% | 66.59% |
| EBIT | 71.91% | 57.03% | 40.78% | 37.40% | 44.56% |
| EBITDA | 75.86% | 51.91% | 33.59% | 33.60% | 46.05% |
| EPS Basic | 85.59% | 83.88% | 98.72% | 98.62% | 97.74% |
| Normalized Basic EPS | 75.58% | 76.40% | 90.83% | 95.55% | 96.64% |
| EPS Diluted | 85.59% | 83.88% | 98.72% | 98.62% | 97.75% |
| Normalized Diluted EPS | 75.58% | 76.40% | 90.83% | 95.55% | 96.64% |
| Average Basic Shares Outstanding | 21.08% | 37.48% | 99.86% | 238.86% | 724.54% |
| Average Diluted Shares Outstanding | 21.08% | 37.48% | 99.86% | 238.86% | 724.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |